The role of peroxiredoxin (PRDX) 4 in the progression of pancreatic cancer

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K16783
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 50010:Tumor biology-related
• Research Institution: Kanazawa Medical University
• Principal Investigator: GUO Xin 金沢医科大学, 医学部, 助教 (40816328)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 膵癌 / Peroxiredoxin 4 / 生存率 / 浸潤 / 増殖

Outline of Final Research Achievements

Pancreatic cancer is the most refractory cancer with the lowest 5-year survival rate. Due to effective anticancer agents with strong toxic side effects, it is urgent to find preventive and effective therapeutic agents with few side effects. In this study, we focused on the relationship between prdx4 and malignant tumors, and investigated the important role of PRDX4 in pancreatic cancer. Analysis in human pancreatic cancer showed that the high expression of prdx4 promoted tumor invasion and progression with a poor prognosis. The plasmid DNAs of PRDX4 gene was inserted into human pancreatic cancer cell lines to enhance the ability of cell proliferation and migration. Finally, the inhibition of PRDX4 expression implys the possibility of clinical application in the treatment of pancreatic cancer.

Free Research Field

実験病理

Academic Significance and Societal Importance of the Research Achievements

酸化ストレスを抑制することは、メタボリックシンドロームを予防することに繋がり、ひいては悪性腫瘍の発生・進展の抑制にも作用することが示唆される。最近、我々はPRDX4と悪性腫瘍の関連性に着目し、さらなるターゲットとして悪性腫瘍動物実験モデルを敷衍させ、PRDX4が肝細胞癌の増殖・進展や予後等と密接な関連性のあることを明らかにし、さらに、PRDX4の過剰発現が肺癌の発生において、重要な促進因子であることも報告し得た。しかし、PRDX4が膵癌との関連性はまだ報告されていない。本研究では初めて膵癌において、抗酸化酵素PRDX4の役割及びそのメカニズムを検討した。